ClinicalTrials.gg
CompletedNCT01082640Updated Sep 25, 2013Results posted

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

A Phase 2 interventional study of Febuxostat and Placebo in Renal Impairment, sponsored by Takeda. Completed at 58 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-25.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Renal Insufficiency by Takeda — 1 open to participants now, 1 under way, none of them phase 3. Renal Insufficiency · Takeda.

Enrollment
4th of 11
96 · median 48
Started
2010
the only one that year
Phase 2
2 of 12
none open now
Registered
4th of 12
by date

Among the 12 studies in Renal Insufficiency by Takeda, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2010, is one of 2 in phase 2, and was the 4th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 12 studies in Renal Insufficiency by Takeda is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Renal Insufficiency by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice daily (BID), on renal function in gout patients with elevated serum urate levels and who have moderate to severe renal impairment.

Read the detailed description

Gout is caused by high levels of uric acid in the body, and is associated with a broad range of conditions including heart disease, chronic kidney disease and high blood pressure. Hyperuricemia, which is defined as an elevation in serum urate levels, develops into gout when urate crystals form in the body and settle in joints and other organs.

Approximately 40-60% of patients with hyperuricemia and gout have some degree of renal impairment. Hyperuricemia has long been associated with renal disease, and chronic hyperuricemia as seen in gout can lead to deposition of urate crystals resulting in diminished renal function.

This study will evaluate the effect of febuxostat on the renal function of patients with hyperuricemia and gout and moderate to severe renal impairment.

All participants must have an average sitting blood pressure measurement less than 160 mmHg systolic and less than 95 mmHg diastolic. All participants must meet the American Rheumatism Association (ARA) diagnostic criteria for gout (subjects with tophi were excluded). Participants are expected to return to the site for approximately 10 visits.

03

Conditions studied

  • Renal Impairment

Keywords

  • Gout
  • physiology
  • Hyperuricemia
  • Uric Acid
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a serum urate greater than 7 mg/dL and a serum creatinine greater than or equal to 1.5 mg at Day -21
  • Must have a history or presence of gout defined as having one or more of the American Rheumatism Association criteria for the diagnosis of gout (the criteria related to tophi have been excluded for the purpose of the study)
  • Must have an estimated (eGFR) of 15 or greater, or less than or equal to 50 mL/min, AND a serum creatinine greater than 1.5 mg/dL at Screening Visit Day -21

Exclusion criteria

Exclusion Criteria:

  • Has secondary hyperuricemia (eg, due to myeloproliferative disorder, or organ transplant)
  • Has tophaceous gout
  • Has a history of xanthinuria
  • Has received aspirin greater than 325 mg/day within 35 days prior to Day 1/Randomization Visit
  • Has known or allergy to allopurinol or any component in its formulation
  • Has known hypersensitivity to febuxostat or colchicine or any components in their formulation
  • Has myocardial infarction or stroke within the 90 days prior to the Screening Visit
  • Has and/or aspartate aminotransferase values greater than 2.0 times the
  • Has end stage renal disease or is likely to be a candidate for dialysis over the 1 year study period
  • Has a serum creatinine less than or equal to 1.5 mg/dL, or an estimated at Day -21 Screening Visit less than 15 mL/min or greater than 50 mL/min as calculated by the central laboratory
  • Is required to take excluded medications
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo-matching capsules, orally, twice daily for up to 12 months.

    Drug: Placebo

  • Experimental
    Febuxostat 30 mg BID

    Febuxostat 30 mg, capsules, orally, twice daily (BID) for up to 12 months.

    Drug: Febuxostat

  • Experimental
    Febuxostat 40/80 mg QD

    Participants initially received febuxostat 40 mg, capsules, once daily (QD) and one placebo-matching capsule QD and remained on this dose for up to 12 months if their serum urate (sUA) was \<6.0 mg/dL at the Day 14 visit. Participants whose sUA was ≥6.0 mg/dL at the Day 14 visit received febuxostat 80 mg, capsule, QD, and one placebo-matching capsule QD at the Month 1 visit, and for the remainder of the study.

    Drug: Febuxostat · Drug: Placebo

Interventions

  • Febuxostat capsules

    Also known as: Uloric, TMX-67

  • DrugPlacebo

    Febuxostat placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Month 12 in Serum Creatinine

    Renal function was assessed by measuring the change from Baseline in serum creatinine. Analyses were conducted by the Central Laboratory.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Change From Baseline to Month 12 in Estimated Glomerular Filtration Rate (eGFR)

    Change from baseline to Month 12 in estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (as calculated by the central laboratory).

    Time frame: Baseline and Month 12

  2. Percentage of Participants With Serum Urate (sUA) Less Than 6 mg/dL at Month 12

    Serum urate concentrations were determined using the enzymatic method as performed by the Central Laboratory.

    Time frame: Month 12

  3. Mean Clearance (CL/F) of Febuxostat at Steady State

    Mean CL/F at steady state were estimated using a population pharmacokinetic (PK) approach, based on 2 PK samples collected prior to dosing, and 4 PK samples collected postdose.

    Time frame: The 2 pre-dose PK samples collected were collected at any 2 of the following visits: Months 3, 6, 9, and/or 12, at -0.25 to 0 hours. The 4 postdose PK samples were collected at Months 3, 6, and/or 9, at 0.25; 0.75 to 2.0; 2.5 to 4.0; and 5 to 12 hours.

  4. Mean Area Under the Concentration-Time Curve During the Dosing Interval (AUC[0-τ]) of Febuxostat at Steady State

    Mean AUC during the dosing interval at steady state was estimated using a population pharmacokinetic (PK) approach, based on 2 PK samples collected prior to dosing, and 4 PK samples collected postdose.

    Time frame: The 2 pre-dose PK samples collected were collected at any 2 of the following visits: Months 3, 6, 9, and/or 12, at -0.25 to 0 hours. The 4 postdose PK samples were collected at Months 3, 6, and/or 9, at 0.25; 0.75 to 2.0; 2.5 to 4.0; and 5 to 12 hours.

07

Results

Posted Sep 25, 2013

Participant flow

Participants took part in the study at 46 investigative sites in the United States from 09 April 2010 to 31 May 2012.

Participant flow — Overall Study
MilestonePlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QD
Started323232
Completed151724
Not completed17158
Withdrew: Adverse event953
Withdrew: Withdrawal by subject332
Withdrew: Major protocol deviation330
Withdrew: Lost to follow-up030
Withdrew: Other213

Outcome measures

PrimaryChange From Baseline to Month 12 in Serum Creatinine

Renal function was assessed by measuring the change from Baseline in serum creatinine. Analyses were conducted by the Central Laboratory.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Month 12 in Serum Creatinine
mg/dLPlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QD
Baseline2.52 ± 0.1262.10 ± 0.1262.22 ± 0.128
Change from Baseline at Month 120.19 ± 0.0940.09 ± 0.0930.23 ± 0.094
Statistical analysis
  • Placebo vs Febuxostat 30 mg BID · ANCOVA · p = 0.459 (No adjustment for multiplicity was made.) · Ls mean difference: -0.10 · 95% CI -0.37 to 0.17The model included treatment as a factor, and the baseline value and prior use of an ARB or an ACEi or none as covariates.
  • Placebo vs Febuxostat 40/80 mg QD · ANCOVA · p = 0.789 (No adjustment for multiplicity was made.) · Ls mean difference: 0.04 · 95% CI -0.23 to 0.30The model included treatment as a factor, and the baseline value and prior use of an ARB or an ACEi or none as covariates.
SecondaryChange From Baseline to Month 12 in Estimated Glomerular Filtration Rate (eGFR)

Change from baseline to Month 12 in estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (as calculated by the central laboratory).

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · mL/min/1.73m²
Change From Baseline to Month 12 in Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73m²PlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QD
Baseline29.31 ± 1.46134.14 ± 1.46134.08 ± 1.484
Change from Baseline at Month 12-2.05 ± 1.1980.33 ± 1.172-0.86 ± 0.190
Statistical analysis
  • Placebo vs Febuxostat 30 mg BID · ANCOVA · p = 0.162 (No adjustment for multiplicity was made.) · Ls mean difference: 2.38 · 95% CI -0.97 to 5.73The model included treatment as a factor, and the baseline value and prior use of an ARB or an ACEi or none as covariates.
  • Placebo vs Febuxostat 40/80 mg QD · ANCOVA · p = 0.485 (No adjustment for multiplicity was made.) · Ls mean difference: 1.19 · 95% CI -2.18 to 4.57The model included treatment as a factor, and the baseline value and prior use of an ARB or an ACEi or none as covariates.
SecondaryPercentage of Participants With Serum Urate (sUA) Less Than 6 mg/dL at Month 12

Serum urate concentrations were determined using the enzymatic method as performed by the Central Laboratory.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Urate (sUA) Less Than 6 mg/dL at Month 12
percentage of participantsPlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QD
Percentage of Participants With Serum Urate (sUA) Less Than 6 mg/dL at Month 12068.845.2
Statistical analysis
  • Placebo vs Febuxostat 30 mg BID · Cochran-Mantel-Haenszel · p = <0.001Prior use of an ARB, ACEi, or none was a stratification variable.
  • Placebo vs Febuxostat 40/80 mg QD · Cochran-Mantel-Haenszel · p = <0.001Prior use of an ARB, ACEi, or none was a stratification variable.
  • Febuxostat 30 mg BID vs Febuxostat 40/80 mg QD · Cochran-Mantel-Haenszel · p = 0.062Prior use of an ARB, ACEi, or none was a stratification variable.
SecondaryMean Clearance (CL/F) of Febuxostat at Steady State

Mean CL/F at steady state were estimated using a population pharmacokinetic (PK) approach, based on 2 PK samples collected prior to dosing, and 4 PK samples collected postdose.

Time frame:
The 2 pre-dose PK samples collected were collected at any 2 of the following visits: Months 3, 6, 9, and/or 12, at -0.25 to 0 hours. The 4 postdose PK samples were collected at Months 3, 6, and/or 9, at 0.25; 0.75 to 2.0; 2.5 to 4.0; and 5 to 12 hours.
Reported as:
Mean · liters/hour
Mean Clearance (CL/F) of Febuxostat at Steady State
liters/hourFebuxostat 30 mg BIDFebuxostat 40 mg QDFebuxostat 80 mg QD
Mean Clearance (CL/F) of Febuxostat at Steady State8.16 ± 2.318.71 ± 2.2110.9 ± 4.70
SecondaryMean Area Under the Concentration-Time Curve During the Dosing Interval (AUC[0-τ]) of Febuxostat at Steady State

Mean AUC during the dosing interval at steady state was estimated using a population pharmacokinetic (PK) approach, based on 2 PK samples collected prior to dosing, and 4 PK samples collected postdose.

Time frame:
The 2 pre-dose PK samples collected were collected at any 2 of the following visits: Months 3, 6, 9, and/or 12, at -0.25 to 0 hours. The 4 postdose PK samples were collected at Months 3, 6, and/or 9, at 0.25; 0.75 to 2.0; 2.5 to 4.0; and 5 to 12 hours.
Reported as:
Mean · hr*µg/mL
Mean Area Under the Concentration-Time Curve During the Dosing Interval (AUC[0-τ]) of Febuxostat at Steady State
hr*µg/mLFebuxostat 30 mg BIDFebuxostat 40 mg QDFebuxostat 80 mg QD
Mean Area Under the Concentration-Time Curve During the Dosing Interval (AUC[0-τ]) of Febuxostat at Steady State3.98 ± 1.214.91 ± 1.298.21 ± 2.30

Adverse events

Collected over From first double-blind dose date and up to 30 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—7/32 (21.9%)20/32 (62.5%)
Febuxostat 30 mg BID—5/32 (15.6%)21/32 (65.6%)
Febuxostat 40/80 mg QD—8/32 (25%)23/32 (71.9%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QD
Acute Myocardial InfarctionCardiac disorders2/320/321/32
Atrial FibrillationCardiac disorders0/320/322/32
Renal Failure AcuteRenal and urinary disorders2/321/321/32
Cardiac Failure CongestiveCardiac disorders0/321/321/32
Cardiogenic ShockCardiac disorders0/320/321/32
Cardiac ArrestCardiac disorders1/320/320/32
Ventricular FibrillationCardiac disorders0/320/321/32
DiarrhoeaGastrointestinal disorders0/320/321/32
Gastrooesophageal Reflux DiseaseGastrointestinal disorders0/321/320/32
Adverse Drug ReactionGeneral disorders0/320/321/32
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QD
Blood creatinine increasedInvestigations1/325/322/32
DiarrhoeaGastrointestinal disorders4/322/324/32
HyperkalaemiaMetabolism and nutrition disorders2/321/324/32
Pain in extremityMusculoskeletal and connective tissue disorders2/323/323/32
NauseaGastrointestinal disorders3/322/320/32
VomitingGastrointestinal disorders3/322/320/32
ArthralgiaMusculoskeletal and connective tissue disorders3/323/323/32
BronchitisInfections and infestations2/323/320/32
HypotensionVascular disorders0/320/323/32
Back painMusculoskeletal and connective tissue disorders1/322/322/32

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QDTotal
Mean66.3 ± 12.0567.3 ± 11.1163.6 ± 8.1565.7 ± 10.57
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QDTotal
Female67619
Male26252677
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QDTotal
Hispanic or Latino3238
Not Hispanic or Latino29302988
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QDTotal
American Indian or Alaska Native0101
Asian0235
Native Hawaiian or Other Pacific Islander2013
Black or African American45716
White25242170
Other1001
Region of Enrollment
Region of Enrollment(participants)PlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QDTotal
United States32323296
Height
Height(cm)PlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QDTotal
Mean172.6 ± 11.55173.8 ± 9.60172.8 ± 9.48173.1 ± 10.16
Weight
Weight(kg)PlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QDTotal
Mean100.7 ± 27.5498.8 ± 19.84102.6 ± 25.85100.7 ± 24.42
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboFebuxostat 30 mg BIDFebuxostat 40/80 mg QDTotal
Mean33.3 ± 6.3632.8 ± 6.4534.2 ± 7.3033.4 ± 6.67

11 further baseline measures are reported on the registry.

08

Study locations

58 sites
  • Birmingham, Alabama, United States
  • Peoria, Arizona, United States
  • Sierra Vista, Arizona, United States
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • Huntington Park, California, United States
  • Irvine, California, United States
  • Lakewood, California, United States
  • Long Beach, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • San Jose, California, United States
  • Tustin, California, United States
  • Arvada, Colorado, United States
  • Westminster, Colorado, United States
  • Wheat Ridge, Colorado, United States
  • Middlebury, Connecticut, United States
  • Brandon, Florida, United States
  • Daytona Beach, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Pinellas Park, Florida, United States
  • Port Charlotte, Florida, United States
  • Port Orange, Florida, United States
  • Augusta, Georgia, United States
  • Conyers, Georgia, United States
  • Dunwoody, Georgia, United States
  • Honolulu, Hawaii, United States
  • Boise, Idaho, United States
  • Evergreen Park, Illinois, United States
  • Springfield, Illinois, United States
  • Valparaiso, Indiana, United States
  • Wichita, Kansas, United States
  • Elizabethtown, Kentucky, United States
  • Paducah, Kentucky, United States
  • Baltimore, Maryland, United States
  • Detroit, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Brooklyn Center, Minnesota, United States
  • Neptune City, New Jersey, United States
  • Morganton, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Fargo, North Dakota, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Bethlehem, Pennsylvania, United States
  • Anderson, South Carolina, United States
  • Greer, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • Houston, Texas, United States
  • Odessa, Texas, United States
  • San Antonio, Texas, United States
  • Danville, Virginia, United States
  • Fairfax, Virginia, United States
  • Richmond, Virginia, United States
  • Williamsburg, Virginia, United States
  • Clarksburg, West Virginia, United States
  • Wauwatosa, Wisconsin, United States
09

References and documents

Publications

  • Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016 Aug;68(8):2035-43. doi: 10.1002/art.39654. PubMed 26894653 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2010
First posted
Mar 8, 2010
Start
Apr 2010
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Sep 25, 2013
Last update
Sep 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01082640
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 8, 2010
Start date
Apr 2010
Primary completion
May 2012
Completion
May 2012
Results posted
Sep 25, 2013
Last update
Sep 25, 2013

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion